Media coverage about Medtronic (NYSE:MDT) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Medtronic earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned news coverage about the medical technology company an impact score of 46.7700689892738 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the media stories that may have impacted Accern’s analysis:
- New Study Shows Superiority of Intrathecal Baclofen Therapy (ITB Therapy(SM)) Over Oral Medication for the Treatment of Severe Post-Stroke Spasticity (finance.yahoo.com)
- Insider Selling: Medtronic plc. (MDT) VP Sells 78,526 Shares of Stock (americanbankingnews.com)
- Stryker Stock: Wall Street Recommendations and Target Price (finance.yahoo.com)
- Medtronic enrols first patient in pain study to optimize spinal cord stimulation (medicalphysicsweb.org)
- FDA Approves Innovative Clinician Programmer for the Medtronic SynchroMed II Intrathecal Drug Delivery System for Chronic Pain and Severe Spasticity (finance.yahoo.com)
Medtronic (NYSE:MDT) traded up $0.24 during trading on Thursday, reaching $85.73. 3,930,314 shares of the company’s stock traded hands, compared to its average volume of 5,594,702. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.40 and a quick ratio of 2.05. The company has a market capitalization of $115,710.00, a P/E ratio of 23.55, a PEG ratio of 2.35 and a beta of 0.99. Medtronic has a 1-year low of $73.59 and a 1-year high of $89.72.
The firm also recently declared a quarterly dividend, which will be paid on Friday, January 19th. Shareholders of record on Friday, December 29th will be paid a $0.46 dividend. This represents a $1.84 annualized dividend and a yield of 2.15%. The ex-dividend date of this dividend is Thursday, December 28th. Medtronic’s dividend payout ratio is presently 50.55%.
MDT has been the subject of several research reports. Bank of America upgraded shares of Medtronic from a “neutral” rating to a “buy” rating in a research report on Tuesday, January 2nd. Royal Bank of Canada cut their target price on shares of Medtronic from $90.00 to $85.00 and set an “outperform” rating for the company in a research report on Monday, October 9th. SunTrust Banks set a $92.00 target price on shares of Medtronic and gave the stock a “buy” rating in a research report on Sunday, November 19th. Jefferies Group reiterated a “buy” rating and issued a $99.00 target price on shares of Medtronic in a research report on Thursday, November 23rd. Finally, Northland Securities reiterated a “hold” rating and issued a $80.00 target price on shares of Medtronic in a research report on Wednesday, November 22nd. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and fifteen have issued a buy rating to the stock. Medtronic has a consensus rating of “Buy” and an average target price of $89.65.
In other news, EVP Bryan C. Hanson sold 16,000 shares of the company’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $79.02, for a total transaction of $1,264,320.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Richard Kuntz sold 78,526 shares of the company’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $86.21, for a total transaction of $6,769,726.46. Following the transaction, the vice president now directly owns 149,761 shares of the company’s stock, valued at $12,910,895.81. The disclosure for this sale can be found here. Insiders sold 152,684 shares of company stock valued at $12,831,076 over the last three months. 0.31% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Medtronic (MDT) Share Price” was originally posted by Markets Daily and is the property of of Markets Daily. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.themarketsdaily.com/2018/01/12/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-medtronic-mdt-share-price.html.
Medtronic Company Profile
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.